{"nctId":"NCT01183143","briefTitle":"Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization","startDateStruct":{"date":"2004-05-11","type":"ACTUAL"},"conditions":["Infertility","Ovulation Induction","In-Vitro Fertilization"],"count":215,"armGroups":[{"label":"GONAL-f®","type":"EXPERIMENTAL","interventionNames":["Drug: GONAL-f®"]}],"interventions":[{"name":"GONAL-f®","otherNames":["Follitropin alpha"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female subjects aged between 18 and 43 years\n* Ambulatory subjects\n* Subjects who are willing to get pregnant and are infertile, that justifies ovarian stimulation treatment for mono-/pauci-follicular development (OI or IUI) or multiple follicular development for IVF/Intracytoplasmic Sperm Injection (ICSI) procedures\n* Subjects who are able to communicate well with the investigator and to comply with the requirements of the entire study\n* Subjects who have given written informed consent, prior to treatment\n\nExclusion Criteria:\n\n* Subjects with enlarged ovaries or cysts unrelated to polycystic ovaries\n* Subjects with extra-uterine pregnancy during the last 3 months\n* Subjects with several endometriosis (Grade III \\& IV)\n* Subjects with history of severe ovarian hyperstimulation syndrome\n* Subjects with history of thromboembolic event\n* Subjects with malformative uterine pathology that could disturb either implantation or pregnancy processes\n* Subjects with premature menopause\n* Subjects with gynecological bleeding of unknown origin\n* Subjects with ovarian, uterine, or mammary cancer\n* Subjects with tumors of the hypothalamus or the pituitary glands\n* Subjects with history of serious allergy or atopic asthma disease\n* Subjects with known allergic reaction against one of the Follicle Stimulating Hormone (FSH) and ingredients,\n* Ongoing pregnant, or breast feeding subjects\n* Subjects who have participated in a trial during the last 3 months","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"43 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Who Self-administered the Investigational Medicinal Product (IMP)","description":"Number of subjects who self-administered the IMP were presented in this outcome measure.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Evaluation of the GONAL-f® Prefilled Pen by the Investigator","description":"Investigator evaluated the use of GONAL-f® prefilled pen in subjects as very satisfactory, satisfactory and average satisfaction.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Evaluation of the Information Given to the Subjects on the Pen's Utilization","description":"Subjects were provided with the information on Pen's utilization via training session and in the form of information brochure. Subjects assessed both the methods using the following responses: satisfactory, satisfactory, unsatisfactory and very unsatisfactory.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Ovarian Stimulation With GONAL-f®","description":"Stimulation duration was defined as the duration (in days) for which subjects underwent GONAL-f® treatment.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Number of Embryos Transferred","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Total and Average Daily Dose of GONAL-f®","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1527","spread":"964"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149.5","spread":"75.9"}]}]}]},{"type":"SECONDARY","title":"Pregnancy Rate in Subjects Receiving Stimulation by Ovulation Induction (OI) or Artificial Insemination (IUI)","description":"Pregnancy rate was defined as the percentage of subjects with diagnosis of pregnancy, who underwent OI/IUI. Clinical pregnancy: Evidence of pregnancy by clinical or ultrasound parameters at 12 weeks after fertilization. Biochemical pregnancy: Evidence of conception based only on biochemical data in the serum or urine before ultrasound evidence of a gestational sac. Ongoing pregnancy was defined when the pregnancy had completed 20 weeks of gestation.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Live Birth","description":"Number of subjects whose stimulation with the IMP resulted in the birth of a baby were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Local Tolerance at GONAL-f ® Injection Site as Assessed by Investigator","description":"Local tolerance at the GONAL-f ® injection site was assessed for the presence of pain, swelling/welt, redness, itch and haematoma.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With at Least 1 Adverse Event","description":"An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerged or worsened relative to baseline (i.e. present at the initial study visit) during a clinical study with an investigational product, regardless of causal relationship and even if no investigational product has been administered.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Taking at Least 1 Concomitant Treatment","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":215},"commonTop":["Injection site haemorrhage","Injection site erythema","Injection site pain","Ovarian hyperstimulation syndrome","Abortion spontaneous NOS"]}}}